Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis

Hanna Graßhoff*, Konstantinos Fourlakis, Sara Comdühr, Gabriela Riemekasten

*Korrespondierende/r Autor/-in für diese Arbeit
2 Zitate (Scopus)

Abstract

Systemic sclerosis (SSc) is a rare connective tissue disorder characterized by immune dysregulation evoking the pathophysiological triad of inflammation, fibrosis and vasculopathy. In SSc, several alterations in the B-cell compartment have been described, leading to polyclonal B-cell hyperreactivity, hypergammaglobulinemia and autoantibody production. Autoreactive B cells and autoantibodies promote and maintain pathologic mechanisms. In addition, autoantibodies in SSc are important biomarkers for predicting clinical phenotype and disease progression. Autoreactive B cells and autoantibodies represent potentially promising targets for therapeutic approaches including B-cell-targeting therapies, as well as strategies for unselective and selective removal of autoantibodies. In this review, we present mechanisms of the innate immune system leading to the generation of autoantibodies, alterations of the B-cell compartment in SSc, autoantibodies as biomarkers and autoantibody-mediated pathologies in SSc as well as potential therapeutic approaches to target these.

OriginalspracheEnglisch
Aufsatznummer2150
ZeitschriftBiomedicines
Jahrgang10
Ausgabenummer9
ISSN2227-9059
DOIs
PublikationsstatusVeröffentlicht - 09.2022

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

DFG-Fachsystematik

  • 2.22-18 Rheumatologie

Fingerprint

Untersuchen Sie die Forschungsthemen von „Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren